TY - JOUR
T1 - Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia – preliminary study
AU - Amiaz, Revital
AU - Kent, Ilan
AU - Rubinstein, Katya
AU - Sela, Ben Ami
AU - Javitt, Daniel
AU - Weiser, Mark
N1 - Publisher Copyright:
© 2015, Israel Journal of Psychiatry and Related Sciences. All rights reserved.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Background: Hypofunction of NMDA receptor-mediated neurotransmission might play a critical role in schizophrenia. Sarcosine, N- methylglycine and inhibitor of the glycine transporter-1 (Gly-T1), has been suggested as a novel treatment for schizophrenia. Methods: Open label sarcosine was added to 22 stabilized patients: 5 patients received 2 gm/d, and 17 received 4gm/d. Pharmacokinetics samples, clinical and cognitive parameters using PANSS, CGI and MCCB were collected for all patients. Results: Significant improvement was observed after one week of treatment on PANSS sub-scale of ’positive symptoms‘ (Z= -2.68; P=0.007) and ’general psychopathology‘ (Z= -3.02; P=0.003), an improvement in PANSS total score and CGI-S showed a trend (Z= -2.72; P=0.06; Z=-2.69; P=0.08). Speed of processing (MCCB subscale) improved significantly (Z=-2.13; P=0.03). Sarcosine exhibited linear kinetics, with a Tmax and t½ of ~1½- 2½ hr and ~1hr, respectively. Limitations: This was a short period, open label pilot study with small sample size per dosage group. Conclusions: Sarcosine is a safe compound and might be efficacious in the treatment of schizophrenia.
AB - Background: Hypofunction of NMDA receptor-mediated neurotransmission might play a critical role in schizophrenia. Sarcosine, N- methylglycine and inhibitor of the glycine transporter-1 (Gly-T1), has been suggested as a novel treatment for schizophrenia. Methods: Open label sarcosine was added to 22 stabilized patients: 5 patients received 2 gm/d, and 17 received 4gm/d. Pharmacokinetics samples, clinical and cognitive parameters using PANSS, CGI and MCCB were collected for all patients. Results: Significant improvement was observed after one week of treatment on PANSS sub-scale of ’positive symptoms‘ (Z= -2.68; P=0.007) and ’general psychopathology‘ (Z= -3.02; P=0.003), an improvement in PANSS total score and CGI-S showed a trend (Z= -2.72; P=0.06; Z=-2.69; P=0.08). Speed of processing (MCCB subscale) improved significantly (Z=-2.13; P=0.03). Sarcosine exhibited linear kinetics, with a Tmax and t½ of ~1½- 2½ hr and ~1hr, respectively. Limitations: This was a short period, open label pilot study with small sample size per dosage group. Conclusions: Sarcosine is a safe compound and might be efficacious in the treatment of schizophrenia.
UR - http://www.scopus.com/inward/record.url?scp=84939430505&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84939430505
SN - 0333-7308
VL - 52
SP - 12
EP - 16
JO - Israel Journal of Psychiatry and Related Sciences
JF - Israel Journal of Psychiatry and Related Sciences
IS - 1
ER -